L-carnosine, a substrate of carnosinase-1, influences glucose metabolism
Controlled trialOther animals
- Design
- Controlled trial
- Subjects
- not stated in abstract (db/db mice; transgenic and supplemented groups)
- Dose used in the study
- not stated in abstract (L-carnosine added to feed)
- Duration
- not stated in abstract
- What was measured
- Fasting glucose, HbA1c, body weight, glycosuria, fasting insulin, insulin resistance and secretion, and beta-cell mass in db/db mice with raised carnosinase (transgenic human CN1 in liver) or with L-carnosine supplementation.
What the authors reported
The authors report that db/db mice expressing human CN1 in the liver developed earlier and sustained rises in fasting glucose and HbA1c and lower body weight from glycosuria, while L-carnosine-supplemented mice developed milder, later-onset diabetes. Fasting insulin was lower in transgenic mice and rose with L-carnosine feeding. Insulin resistance and insulin secretion were not significantly changed. Beta-cell mass correlated with L-carnosine levels. They conclude that effects of human CN1 variants on diabetic nephropathy may partly act through altered glucose metabolism.
Limits of this study
Mouse model of type 2 diabetes; group sizes and dose not stated in the abstract. Rodents lack serum carnosinase, so oral results do not carry over to people. Full text not read.
Source
PubMed 17601992 · doi:10.2337/db07-0177
Entry checked against PubMed abstract (E-utilities) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.